ThomasCrawfordMarburyMD

Nephrology • Orlando, FL

Orlando Clinical Research Center

Join to view full profile

Dr. Marbury is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Marbury's full profile

Already have an account?

Office
5055 S Orange Ave

Orlando, FL 32809
Phone+1 407-472-0227

Fax+1 407-240-9846
Is this information wrong?

Education & Training

University of FloridaFellowship, Nephrology, 1977 - 1978
University of Texas at Austin Dell Medical SchoolInternship, Internal Medicine, 1974 - 1975
McGovern Medical School at UTHealthClass of 1973

Certifications & Licensure

FL State Medical License 1976 - 2025
TX State Medical License 1974 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Nephrology

Clinical Trials

Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Start of enrollment: 2005 Nov 01
Completed
Phase 2
Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex® Start of enrollment: 2007 Nov 01
Completed
Phase 1
Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction Start of enrollment: 2007 Apr 30
Terminated
Phase 1, Phase 2
Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects Start of enrollment: 2008 Dec 01
Completed
Phase 1
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil Start of enrollment: 2010 May 01
Completed
Phase 1
A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function Start of enrollment: 2010 Oct 01
Completed
Phase 1
A Study of Fostamatinib in Subjects With Impaired Kidney Function Start of enrollment: 2010 Nov 01
Completed
Phase 1
Effect of Hepatic Impairment on LDK378 Pharmacokinetics Start of enrollment: 2014 Jan 01
Completed
Phase 1
MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function Start of enrollment: 2014 Mar 01
Terminated
Phase 1
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects Start of enrollment: 2014 Mar 01
Completed
Phase 1
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects Start of enrollment: 2014 Mar 01
Completed
Phase 1
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects Start of enrollment: 2013 Oct 01
Completed
Phase 1
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Start of enrollment: 2014 Jul 01
Completed
Phase 2
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline Start of enrollment: 2014 Aug 01
Completed
Phase 1
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function Start of enrollment: 2015 Jun 12
Completed
Phase 1
A Study of LY3113593 in Participants With Chronic Kidney Disease Start of enrollment: 2015 Nov 17
Completed
Phase 1
Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. Start of enrollment: 2015 Dec 21
Completed
Phase 1
PK Study of T-817 in Subjects With Hepatic Impairment Start of enrollment: 2016 Feb 01
Completed
Phase 1
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Start of enrollment: 2016 Oct 01
Completed
Phase 2
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2018 Mar 01
Completed
Phase 1
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2017 Jan 11
Withdrawn
Phase 1
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients Start of enrollment: 2017 Oct 01
Completed
Phase 1, Phase 2
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function Start of enrollment: 2017 Dec 12
Completed
Phase 1
A Phase 1 AVB-S6-500 Safety and Tolerability Study Start of enrollment: 2018 Jan 31
Completed
Phase 1
Study of Danicopan in Participants With Hepatic Impairment Start of enrollment: 2018 May 01
Completed
Phase 1
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects Start of enrollment: 2022 Apr 25
Completed
Phase 1
Roles: Contact
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day Start of enrollment: 2022 Mar 29
Completed
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate Intravenous: Equivalence to Administration via Dialysate.
Thomas Marbury, Fred van Heuveln, Eric van der Horst, Raymond Pratt> ;Journal of Clinical Pharmacology. 2021 Nov 7
8 citations
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment.
Mohammad Hossain, Courtney Tiffany, Yu Tao, Aline Barth, Thomas Marbury, Richard A. Preston, Etienne Dumont> ;Clinical Pharmacology in Drug Development. 2021 Jun 1
3 citations
Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
Xinhui Chen, Xiaoming Cui, Nathalie Pognan, Michelle Quinlan, Shruti Kapoor, Gholamreza Rahmanzadeh, Monica Giovannini, Thomas Marbury> ;British Journal of Clinical Pharmacology. 2021 May 27
6 citations
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis
Wolfgang W Wicha, Thomas Marbury, James A. Dowell, Jared L. Crandon, Cathie Leister, James Ermer, Steven P Gelone> ;Pharmacotherapy. 2021 May 1
6 citations
Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function.
Wolfgang W Wicha, Thomas Marbury, James A. Dowell, Jared L. Crandon, Cathie Leister, James Ermer, Steven P Gelone> ;Pharmacotherapy. 2021 May 1
6 citations
Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
Richard A. Preston, Thomas Marbury, Ganesh Balaratnam, Michelle Green, Sandy Dixon, Josh Lehrer-Graiwer, Carla Washington> ;Journal of Clinical Pharmacology. 2021 Apr 1
6 citations
Effect of severe renal impairment on the pharmacokinetics of brigatinib
Neeraj Gupta, Michael J. Hanley, David Kerstein, Meera Tugnait, Narayana I. Narasimhan, Thomas Marbury, Karthik Venkatakrishnan> ;Investigational New Drugs. 2021 Mar 20
5 citations
NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients.
Sonomi Maruyama, Thomas Marbury, Jeffrey J. Connaire, Daniel Ries, William Maxwell, Curtis Rambaran> ;Kidney International Reports. 2021 Mar 1
24 citations
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
Daniel Tatosian, Ka Lai Yee, Zufei Zhang, Kate Mostoller, Erina Paul, Santosh C. Sutradhar, Patrick Larson, Aparna Chhibber, Jianzhong Wen, Ya-Juan Wang, Michael E. La...> ;Clinical Pharmacology and Therapeutics. 2021 Feb 1
9 citations
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib
Nithya Srinivas, April M. Barbour, Noam Epstein, Gongfu Zhou, Susan Petusky, Zhinyin Xun, Brad Yuska, Thomas Marbury, Xuejun Chen, Swamy Yeleswaram, Naresh Punwani> ;Journal of Clinical Pharmacology. 2020 Aug 1
11 citations
Pharmacokinetics of Gepotidacin in Renal Impairment
Mohammad Hossain, Courtney Tiffany, Aparna Raychaudhuri, Dung Nguyen, Guoying Tai, Harry Alcorn, Richard A. Preston, Thomas Marbury, Etienne Dumont> ;Clinical Pharmacology in Drug Development. 2020 Jul 1
7 citations
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilasta...
Pratik Bhagunde, Francheska Colon-Gonzalez, Yang Liu, Jin Wu, Shiyao Sherrie Xu, Graigory Garrett, Patricia Jumes, Kenneth C. Lasseter, Thomas Marbury, Matthew L. Rizk...> ;British Journal of Clinical Pharmacology. 2020 May 1
4 citations
Pharmacokinetics and Safety of the Novel Selective Progesterone Receptor Modulator Vilaprisan in Participants With Renal Impairment.
Marcus-Hillert Schultze-Mosgau, Kenneth C. Lasseter, Thomas Marbury, Stephanie Loewen, Kai Riecke> ;Journal of Clinical Pharmacology. 2020 Aug 1
1 citations
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects
Peter L. Bonate, Charles Van Sant, Kathy Cho, Erin C. Zook, Larry R. Smith, Sou Boutsaboualoy, Ming Ye, Xuegong Wang, Ruishan Wu, Anne Koester, Diane Rammelsberg, Rona...> ;Clinical Pharmacology in Drug Development. 2020 Mar 23
13 citations
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
Ying C. Ou, Richard A. Preston, Thomas Marbury, Zhiyu Tang, William Novotny, Manal Tawashi, Ta Kai Li, Srikumar Sahasranaman> ;Leukemia & Lymphoma. 2020 Feb 7
12 citations
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Juki Ng, W. Rachel Duan, Thomas Marbury, Jeffrey Schmidt, Cheri E. Klein> ;Clinical Pharmacology in Drug Development. 2019 Nov 1
14 citations
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
Sheryl Trueman, Mohamed-Eslam F. Mohamed, Tian Feng, Ana P. Lacerda, Thomas Marbury, Ahmed A. Othman> ;Journal of Clinical Pharmacology. 2019 Sep 1
9 citations
Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis.
Katie Zomorodi, Dan Chen, Lawrence Lee, Kenneth C. Lasseter, Thomas Marbury> ;Journal of Clinical Pharmacology. 2019 Aug 1
19 citations
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Mohamed-Eslam F. Mohamed, Sheryl Trueman, Tian Feng, Jaclyn K Anderson, Thomas Marbury, Ahmed A. Othman> ;Journal of Clinical Pharmacology. 2019 Jun 1
41 citations
Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease
Matthew J. Sheetz, Philip Barrington, Sophie Callies, Paul Berg, Juliet McColm, Thomas Marbury, Brian S. Decker, Gregory L. Dyas, Stephanie Marie Truhlar, Robert J. Be...> ;British Journal of Clinical Pharmacology. 2019 May 1
15 citations
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
Ahmed Salem, Nimita Dave, Thomas Marbury, Beibei Hu, Dale Miles, Suresh Agarwal, Orlando F. Bueno, Rajeev M. Menon> ;Clinical Pharmacokinetics. 2019 Aug 1
9 citations
Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment
Matthew P. Kosloski, Haoyu Wang, David Pugatch, Federico J. Mensa, E.J. Gane, Eric Lawitz, Thomas Marbury, Richard A. Preston, Jens Kort, Wei Liu> ;European Journal of Clinical Pharmacology. 2019 Feb 6
The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.
Eric Lawitz, Mohamed Bidair, Thomas Marbury, Christopher T. Jones, Avantika Barve, Baldur Magnusson, David T. Barkan, Ursula Bodendorf, Kathryn Rene Bracken, Erica Can...> ;Clinical Therapeutics. 2018 Sep 1
7 citations
Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin
Kenneth Duchin, Giorgio Senaldi, Vance Warren, Thomas Marbury, Kenneth C. Lasseter, Hamim Zahir> ;Clinical Drug Investigation. 2018 Aug 31
8 citations
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
William B. Smith, Jesse Hall, Jolene Kay Berg, Michal Kazimir, Amy Yamamoto, Susan P. Walker, Caroline A. Lee, Zancong Shen, David M. Wilson, Dongmei Zhou, Michael Gil...> ;Clinical Drug Investigation. 2018 Aug 1
Join now to see all

Hospital Affiliations

Orlando Health Orlando Regional Medical CenterOrlando, Florida

ThomasCrawfordMarburyMD

Dr. Marbury is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.